Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9301248 | 1.00 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL247234 | 1.00 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL7481310 | 1.00 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL7481306 | 1.00 | HMGCR (0.74) | HMGCRRXRA | |
| SCHEMBL10049194 | 0.89 | HMGCR (0.60) | HMGCRRXRA | |
| SCHEMBL13847591 | 0.89 | HMGCR (0.66) | HMGCR | |
| SCHEMBL13994086 | 0.88 | HMGCR (0.61) | HMGCR | |
| SCHEMBL13524825 | 0.88 | HMGCR (0.65) | HMGCR | |
| SCHEMBL13994087 | 0.88 | HMGCR (0.65) | HMGCR | |
| SCHEMBL14207592 | 0.88 | HMGCR (0.61) | HMGCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 55 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115792001-B | Analytical method for determining pitavastatin tert-butyl ester related substances by utilizing HPLC | 徐州万邦金桥制药有限公司 | 2025-05-09 | — | — | CN | claimed |
| CN-115792001-A | Analysis method for determining pitavastatin tert-butyl ester related substances by using HPLC | 徐州万邦金桥制药有限公司 | 2023-03-14 | — | — | CN | claimed |
| US-8853405-B2 | Crystalline forms of pitavastatin calcium | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 2014-10-07 | — | — | US | claimed |
| US-20140005402-A1 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | NISSAN CHEMICAL INDUSTRIES, LTD. (JP) | 2014-01-02 | — | — | US | claimed |
| CN-120000601-A | Pitavastatin calcium orally disintegrating tablet composition as well as preparation method and application thereof | 广东万泰科创药业有限公司 | 2025-05-16 | — | — | CN | disclosed |
| CN-115792001-B | Analytical method for determining pitavastatin tert-butyl ester related substances by utilizing HPLC | 徐州万邦金桥制药有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-115792001-A | Analysis method for determining pitavastatin tert-butyl ester related substances by using HPLC | 徐州万邦金桥制药有限公司 | 2023-03-14 | — | — | CN | disclosed |
| EP-1472227-B1 | PROCESS FOR THE MANUFACTURE OF ORGANIC COMPOUNDS | NOVARTIS AG (CH) | 2016-04-27 | — | — | EP | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8487105-B2 | Process for preparing pitavastatin, intermediates and pharmaceuctically acceptable salts thereof | MSN LABORATORIES LIMITED (IN) | 2013-07-16 | — | — | US | disclosed |
| US-8476432-B2 | Process for the preparation of HMG-COA reductase inhibitors and intermediates thereof | YUHAN CORPORATION (KR) | 2013-07-02 | — | — | US | disclosed |
| EP-2588474-A2 | PROCESS FOR THE PREPARATION OF HMG-COA REDUCTASE INHIBITORS AND INTERMEDIATES THEREOF | Yuhan Corporation (KR) | 2013-05-08 | — | — | EP | disclosed |
| WO-1995011898-A1 | CONDENSED PYRIDINE TYPE MEVALONOLACTONE INTERMEDIATE AND PROCESS FOR ITS PRODUCTION | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1995-05-04 | — | — | WO | disclosed |
| US-5369109-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-11-29 | — | — | US | disclosed |
| EP-0475627-B1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEM RES (JP) | 1994-10-19 | — | — | EP | disclosed |
| US-5284953-A | Treatment and prevention of hyperlipemia and arteriosclerosis | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1994-02-08 | — | — | US | disclosed |
| US-5276154-A | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1994-01-04 | — | — | US | disclosed |
| EP-0535548-A1 | Inhibitor of atherosclerotic intimal thickening | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1993-04-07 | — | — | EP | disclosed |
| EP-0520406-A1 | Diastereomer salt of optically active quinolinemevalonic acid | NISSAN CHEMICAL INDUSTRIES LTD. (JP) | 1992-12-30 | — | — | EP | disclosed |
| EP-0475627-A1 | Optically active esters of 7-substituted 3,5-difunctionalized 6-heptenoic acids | SAGAMI CHEMICAL RESEARCH CENTER (JP) | 1992-03-18 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140005402-A1 | CRYSTALLINE FORMS OF PITAVASTATIN CALCIUM | CTSC, CACYBP, CA4 | HMGCR 345/4885RXRA 3154/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.